March/April 2025 CLP Tech Guide: Urinalysis and Toxicology
The March/April 2025 issue of Clinical Lab Products features a comprehensive Tech Guide highlighting products from five top lab providers.
The March/April 2025 issue of Clinical Lab Products features a comprehensive Tech Guide highlighting products from five top lab providers.
Healthy.io's kidney test demonstrated 96.4% sensitivity in detecting albuminuria, showcasing its potential to improve early detection of CKD.
Researchers have developed a novel metasurface biosensor platform that improves the detection and monitoring of chronic kidney disease.
Nanostics announced an agreement with Alberta Health Services to help drive diagnostic and prognostic innovations in urological care.
Read MoreThe new drug screening technique can rapidly detect the presence of 40 forensically relevant drugs from urine samples.
Read MoreTianeptine is often described as “gas-station dope” and products containing tianeptine commonly use the street names of “ZaZa” or “Tianna.”
Read MorePathogenDx’s UTI test is built on its D3 Array Platform. The multiplex test has a quick turnaround time with less waste.
Read MoreThe new panel from Quest tests for 88 compounds, and covers a broad array of drug classes, and other illicit additives.
Read MoreThis product design aims to transform workflows, expediting results for labs tasked to provide care for victims of drug-facilitated crimes.
Read MoreResearchers reported the enhanced performance of urinary biomarkers compared to plasma biomarkers for disease detection.
Read MoreShenzhen Superbio Technology received FDA clearance for a point-of-care instrument intended for the detection of fentanyl in human urine.
Read MoreKeystone Lab has officially added xylazine to its in-house urine clinical toxicology menu.
Read MoreHarmGuard FX is a single, low-cost test strip that provides an affordable, reliable way for people to test for fentanyl and xylazine.
Read MoreSelf-sampling with the Colli-Pee device could significantly expand access to cervical cancer screening for underserved and rural populations.
Read MoreIntelligent Bio Solutions Inc. has announced plans to add fentanyl to the substances detected by its Fingerprinting Drug Screening System.
Read MoreFDA has granted Breakthrough Device Designation to EarlyTect BCD as a non-invasive, urine-based diagnostic for bladder cancer in patients with hematuria.
Read MoreParkway Clinical Laboratories Inc. (PCL), has launched Xylazine testing via LCMSMS confirmation testing on urine specimens.
Read MoreClinisys has acquired Promium, a provider of laboratory information management systems for environmental analytical testing laboratories.
Read More